Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
139 hedge funds and large institutions have $755M invested in Intra-Cellular Therapies Inc. in 2020 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 64 increasing their positions, 26 reducing their positions, and 25 closing their positions.
146% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 26
41% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $7.69M
32% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 25
5% more funds holding
Funds holding: 133 → 139 (+6)
42% less capital invested
Capital invested by funds: $1.3B → $755M (-$546M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$30.8M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$29.7M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$25M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.6M |
| 5 |
SC
Samlyn Capital
New York
|
+$19.3M |
Top Sellers
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$20.1M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$13.9M |
| 3 |
Morgan Stanley
New York
|
-$7.93M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$7.85M |
| 5 |
CCM
Consonance Capital Management
New York
|
-$6.96M |
ITCI Hedge Fund Activity: Q1 2020 in Review
139 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2020, worth a combined $755M — down 42% from $1.3B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new ITCI positions and 25 closed out — a net gain of 8 holders — while 64 added to existing stakes and 26 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $30.8M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $20.1M sold.
- 139 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2020, up from 133 in Q4 2019.
- Funds reported $755M of Intra-Cellular Therapies Inc. stock for Q1 2020, down 42% quarter-over-quarter.
- 33 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2020 and 25 closed out, a net change of +8 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q1 2020 was Fidelity Investments, an estimated $30.8M added.
- The largest Intra-Cellular Therapies Inc. seller in Q1 2020 was Acuta Capital Partners, an estimated $20.1M sold.
Based on aggregated 13F filings for Q1 2020.